Opinions The Panic-Proof Portfolio (Stockchase Research)
Genmab ADRGMABTOP PICKMar 10, 2026
Stock price when the opinion was issued
As of Jun 02, 2026. Market Open.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentOur PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.
Premium contentGMAB is a biotech company based in the Netherlands producing human antibody treatments for cancer. It collects a royalty agreement with J&J that pays $14.3 billion, of which over half originates from the US and the balance from Europe. This is allowing for cash reserves to grow aggressively, while debt is retired. Annual EPS growth exceeds 28% over the past five years and analysts see growth over 20% over the next five. It trades at 16x earnings, 3.2x book and supports a 28% ROE. We recommend setting a stop-loss at $24, looking to achieve $37 -- upside potential of 23%. Yield 0%
(Analysts’ price target is $37.42)
Following recently released earnings, we reiterate GMAB as a TOP PICK. The Danish based pharmaceutical company reported a 19% increase in revenues, thanks to a 54% increase in the sales of proprietary antibody treatments for cancer. Cash reserves grew while shares were aggressively bought back. It trades at 18x earnings, 3x book and supports a 17% ROE. We continue to recommend a stop at $24, looking to achieve $37 — upside potential of 32%. Yield 0%
(Analysts’ price target is $36.75)